Search research articles
Contact Us
Filters
Showing results (151-160 of 161) with videos related to
Page
of 17
Sort By:
Journal of the National Cancer Institute
|
February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
Oncotarget
|
December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
Juliette Palle, David Tougeron, Astrid Pozet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André, Armand de Gramont, Dewi Vernerey, et al.
BMC Cancer
|
August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
Stefano Kim, Marine Jary, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André, Dewi Vernerey, Laurent Mineur, et al.
The Oncologist
|
June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Camille Evrard, Antoine Pelras, Simon Rivet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
Clinical Trials (London, England)
|
August 25, 2018
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Andrew Bottomley, Madeline Pe, Jeff Sloan, et al.
The Lancet. Oncology
|
March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
Emil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 161) with videos related to
Sort By:
Page
of 17
Journal of the National Cancer Institute
|
February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
Oncotarget
|
December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
Juliette Palle, David Tougeron, Astrid Pozet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André, Armand de Gramont, Dewi Vernerey, et al.
BMC Cancer
|
August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
Stefano Kim, Marine Jary, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André, Dewi Vernerey, Laurent Mineur, et al.
The Oncologist
|
June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Camille Evrard, Antoine Pelras, Simon Rivet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
Clinical Trials (London, England)
|
August 25, 2018
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Andrew Bottomley, Madeline Pe, Jeff Sloan, et al.
The Lancet. Oncology
|
March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
Emil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Page
of 17